Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients
NCT06121479 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-09-29
Summary
The goal of this clinical trial is to compare the nutritional parameters after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL.
The main questions it aims to answer are:
1. Would thigh muscle thickness change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL?
2. Would triceps skin fold thickness, mid-arm circumferences, mid-arm muscle circumferences, skeletal muscle mass, appendicular skeletal muscle mass, skeletal muscle index and fat mass change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL?
3. Would handgrip strength change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL?
4. Would serum albumin change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL?
5. Would score for cirrhotic severity such as Model for End-Stage Liver Disease-Sodium Score (MELD-Na score) and Child Turcotte Pugh Score change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL?
Participants will be asked to do following tasks:
1. Participants will be asked for basic information such as age, place of residence, and contact telephone number.
2. Participants will undergo measurements of weight, height, body mass index, skinfold thickness on the arms, circumference of the arms and legs, muscle mass, and body fat content using a body composition analyzer, both at the beginning and end of the research study.
3. Participants will perform grip strength measurements, at both the beginning and end of the research study.
4. Participants will undergo laboratory tests, including a complete blood count, liver and kidney function tests, blood clotting factors, and blood mineral levels, with a total blood volume of approximately 15 milliliters (1 tablespoon), collected twice during the study (at the beginning and end).
5. Participants will be administered supplements containing branched-chain amino acids (BCAA) twice a day for a total of 12 weeks.
6. Participants will be appointed for follow-up during the study, totaling 2 appointments at weeks 4 and 12. Side effects related to medication will be asked.
7. Participants will undergo ultrasound measurements of the right thigh to assess thigh muscle thickness, both at the beginning and end of the research study.
8. Participants will will complete questionnaires to assess your overall quality of life twice, both at the beginning and end of the research study.
Conditions
- Decompensated Cirrhosis and Ascites
Interventions
- DRUG
-
Branched-chain amino acid
Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
Sponsors & Collaborators
-
Mahidol University
lead OTHER
Principal Investigators
-
Phunchai Charatcharoenwitthaya, M.D. · Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-13
- Primary Completion
- 2025-09-23
- Completion
- 2025-12-31
Countries
- Thailand
Study Locations
More Related Trials
-
Effect of Branched-chain Amino Acid Supplementation and Exercise on Muscle Quantity and Quality in Cirrhosis
NCT06088550 ·Status: COMPLETED ·Phase: NA
-
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C
NCT03633279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
TIPS With or Without BCAA
NCT07281846 ·Status: RECRUITING ·Phase: NA
-
Characterization of the Nutritional Status in the Patient With Liver Cirrhosis
NCT04073693 ·Status: COMPLETED ·Phase: NA
-
Study of the Benefit of Exercise and Aminoacid Supplements in Cirrhotic Patients
NCT01060813 ·Status: COMPLETED ·Phase: NA
-
Role of Branched-chain Amino Acids Infusion as Adjunct Therapy Post Liver Surgery for Patients in Intensive Care Unit
NCT03448848 ·Status: COMPLETED ·Phase: NA
-
Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
NCT05700695 ·Status: COMPLETED ·Phase: PHASE1
-
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
NCT05249374 ·Status: COMPLETED ·Phase: PHASE1
-
Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial
NCT03892070 ·Status: UNKNOWN ·Phase: NA
-
Short Term Feeding for Asian Patients With Liver Cirrhosis
NCT01165073 ·Status: COMPLETED ·Phase: NA
-
Sarcopenia and Cirrhosis
NCT02132962 ·Status: COMPLETED ·Phase: NA
-
Impact of Dietary Assessment and Intervention on Outcomes in Liver Cirrhosis Patients
NCT05259930 ·Status: RECRUITING ·Phase: NA
-
Albumin Infusion in Inpatients With Decompensated Cirrhosis
NCT05719051 ·Status: UNKNOWN
-
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease
NCT02140294 ·Status: COMPLETED ·Phase: NA
-
Plasma Free Amino Acids in Patients With Hepatic Encephalopathy
NCT03306498 ·Status: UNKNOWN
-
The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
NCT01440829 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of High Dose Albumin Therapy in Improving Liver Transplant-free Survival in Patients With Acute Decompensation of Cirrhosis
NCT05956197 ·Status: UNKNOWN
-
Effect of Whey Protein Versus Egg Albumen Protein Challenge on Blood Ammonia Level in Patients of Decompensated Ethanol Related Cirrhosis.
NCT07299110 ·Status: RECRUITING ·Phase: NA
-
Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk
NCT06128421 ·Status: RECRUITING ·Phase: NA
-
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
NCT06553456 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites
NCT04058613 ·Status: UNKNOWN ·Phase: NA
-
Nutritional Interventions in Patients With Alcohol-associated Hepatitis
NCT06131177 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure
NCT07270874 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Molecular Mechanism of Exercise in Cirrhosis
NCT05982769 ·Status: RECRUITING ·Phase: NA
-
Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis
NCT01288794 ·Status: COMPLETED ·Phase: PHASE4